128 related articles for article (PubMed ID: 31264321)
1. A biotinylated peptide, BP21, alleviates hypotension in anaphylactic mice.
Sato A; Ebina K
J Pept Sci; 2019 Aug; 25(8):e3197. PubMed ID: 31264321
[TBL] [Abstract][Full Text] [Related]
2. A biotinylated peptide, BP21, as a novel potent anti-anaphylactic agent targeting platelet-activating factor.
Sato A; Ebina K
J Pept Sci; 2017 Sep; 23(9):727-735. PubMed ID: 28627122
[TBL] [Abstract][Full Text] [Related]
3. Synthetic biotinylated peptide compounds derived from Asp-hemolysin: novel potent inhibitors of platelet-activating factor.
Sato A; Kumagai T; Aoki J; Ebina K
Eur J Pharmacol; 2012 Jun; 685(1-3):205-12. PubMed ID: 22542654
[TBL] [Abstract][Full Text] [Related]
4. Biotinylated peptides substituted with D-amino acids with high stability as anti-anaphylactic agents targeting platelet-activating factor.
Sato A; Fukase T; Ebina K
J Pept Sci; 2022 Oct; 28(10):e3412. PubMed ID: 35437860
[TBL] [Abstract][Full Text] [Related]
5. A synthetic biotinylated peptide, BP21, inhibits the induction of mRNA expression of inflammatory substances by oxidized- and lyso-phosphatidylcholine.
Sato A; Kumagai T; Ebina K
Drug Dev Res; 2014 Jun; 75(4):246-56. PubMed ID: 24890951
[TBL] [Abstract][Full Text] [Related]
6. An endothelin-3-related synthetic biotinylated pentapeptide as a novel inhibitor of platelet-activating factor.
Sato A; Suzuki T; Oikawa K; Ohta R; Ebina K
Eur J Pharmacol; 2013 Aug; 714(1-3):142-7. PubMed ID: 23792041
[TBL] [Abstract][Full Text] [Related]
7. Biotinylated heptapeptides substituted with a D-amino acid as platelet-activating factor inhibitors.
Sato A; Yokoyama I; Ebina K
Eur J Pharmacol; 2015 Oct; 764():202-207. PubMed ID: 26142829
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
9. Mouse anaphylactic shock is caused by reduced cardiac output, but not by systemic vasodilatation or pulmonary vasoconstriction, via PAF and histamine.
Wang M; Shibamoto T; Tanida M; Kuda Y; Kurata Y
Life Sci; 2014 Oct; 116(2):98-105. PubMed ID: 25252221
[TBL] [Abstract][Full Text] [Related]
10. PAF, rather than histamine, participates in mouse anaphylactic hypotension.
Shibamoto T; Liu W; Cui S; Zhang W; Takano H; Kurata Y
Pharmacology; 2008; 82(2):114-20. PubMed ID: 18583921
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms for hypothermia during anaphylactic hypotension in awake rats.
Shibamoto T; Ono M; Tanida M; Kuda Y; Kurata Y
Am J Physiol Regul Integr Comp Physiol; 2023 Nov; 325(5):R446-R455. PubMed ID: 37602385
[TBL] [Abstract][Full Text] [Related]
12. Involvement of splanchnic vascular bed in anaphylactic hypotension in anesthetized BALB/c mice.
Liu W; Takano H; Shibamoto T; Cui S; Zhao ZS; Zhang W; Kurata Y
Am J Physiol Regul Integr Comp Physiol; 2007 Nov; 293(5):R1947-53. PubMed ID: 17715178
[TBL] [Abstract][Full Text] [Related]
13. Effect of the hetrazepinoic platelet-activating factor antagonist Bepafant (WEB 2170) in models of active and passive anaphylaxis in mice and guinea pigs.
Heuer HO
Lipids; 1991 Dec; 26(12):1374-80. PubMed ID: 1819736
[TBL] [Abstract][Full Text] [Related]
14. Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge.
Heuer H; Casals-Stenzel J
Agents Actions Suppl; 1988; 23():207-15. PubMed ID: 3262991
[TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
Doebber TW; Wu MS; Biftu T
J Immunol; 1986 Jun; 136(12):4659-68. PubMed ID: 3011900
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase CK2/PTEN pathway plays a key role in platelet-activating factor-mediated murine anaphylactic shock.
Kang NI; Yoon HY; Kim HA; Kim KJ; Han MK; Lee YR; Hwang PH; Soh BY; Shin SJ; Im SY; Lee HK
J Immunol; 2011 Jun; 186(11):6625-32. PubMed ID: 21531890
[TBL] [Abstract][Full Text] [Related]
17. Effects of WEB 2086, a novel antagonist of platelet activating factor, in active and passive anaphylaxis.
Casals-Stenzel J
Immunopharmacology; 1987 Apr; 13(2):117-24. PubMed ID: 3597059
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of a PAF antagonist CV-3988 on active and passive anaphylactic shock in various mouse strains.
Arimura A; Harada M
Lipids; 1991 Dec; 26(12):1386-90. PubMed ID: 1819738
[TBL] [Abstract][Full Text] [Related]
19. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions.
Arias K; Baig M; Colangelo M; Chu D; Walker T; Goncharova S; Coyle A; Vadas P; Waserman S; Jordana M
J Allergy Clin Immunol; 2009 Aug; 124(2):307-14, 314.e1-2. PubMed ID: 19409603
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
